Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Myriad Genetics, Inc. (MYGN) -- Ignore unavailable to you. Want to Upgrade?

To: sim1 who wrote (2331)	1/28/2011 8:50:37 PM
From: tom pope	Respond to of 2355

That's quite interesting, Stuart, it puts a possibly different perspective on the Sanofi bomb. I had some MYGN that I sold yesterday evening - that was a good thing, but it wasn't because of any particular perspicacity. I'd held NVS thru its lackluster earnings and gloomy forecasts, and was determined not to make the same mistake two days in a row. Actually I was lucky with NVS - lost less than I expected after the earnings news appeared on the wire. MYGN would have been a disaster. Thank you NVS for triggering my caution.

To: sim1 who wrote (2331)	1/30/2011 10:40:56 AM
From: Doctor Zeus	Respond to of 2355

Not necessarily a negative for MYGN 'Sanofi’s results and AstraZeneca’s trial halt in breast cancer are a “negative signal” for this family of drugs having a broad application in oncology, said Navid Malik' The key word is 'broad'. Sanofi went for a broader indication, whilst MYGN focus is only on the BRCA mutations. I believe the Abbott test will only focus on BRCA mutants. Moreover, the Sanofi trial is yet to be analysed to see if the BRCA mutants responded or not. If they did respond, it could turn out to be a net positive for MYGN!